Radiopharm Theranostics (ASX: RAD) managing director and CEO Riccardo Canevari joins Small Caps to discuss the company’s progress and plans for its novel radiopharmaceuticals for diagnostic and therapeutic applications in areas of high unmet need.

The company has collared an agreement to secure Terbium-161 isotope from TerThera, which will be linked to Radiopharm’s RAD 602 therapeutic for treating brain cancers.

A clinical trial of RAD 602 is due to begin later this year, and Radiopharm is also researching other novel radiopharmaceuticals for complex and hard to treat cancers.

Articles:
https://smallcaps.com.au/radiopharm-theranostics-supply-deal-terthera-terbium-161-isotope/
https://smallcaps.com.au/radiopharm-theranostics-genesiscare-develop-solutions-hard-to-treat-cancers/
https://smallcaps.com.au/radiopharm-theranostics-acquires-pharma15-us4m/

For more information on Radiopharm Theranostics: https://smallcaps.com.au/stocks/RAD/

See omnystudio.com/listener for privacy information.